Outcome of myeloma patients with COVID-19 on active lenalidomide-based therapy: Does lenalidomide protect from severe COVID-19?

Patients with haematological cancers and concurrent coronavirus disease 2019 (COVID-19) reportedlyhave poor outcomes as indicated by high hospitalisation rates, high case fatality rates in mechanically ventilated patients, and a high mortality rate of 10% [1–3]. A recent small study reported a high mortality rate among patients with myeloma and concurrent COVID-19 infection [4]. Interestingly, one large study reported that active or recent chemotherapy was not a predictor of severe disease, whereas checkpoint inhibitor therapy and age over 65 years were associated with adverse outcomes [1]. Here we describe the outcomes of three consecutive patients with myeloma and concurrent COVID-19 infection admitted at our tertiary care centre between April and June 2020, whilst on lenalidomide-based therapy, two of whom underwent autologous stem cell transplant, with at least 30 days of followup.

• Tipo de recurso: Article of investigation
• Fecha de publicación: 2020
• Institución: Universidad de Bogotá Jorge Tadeo Lozano
• Repositorio: Expeditio: repositorio UTadeo
• Idioma: eng
• OAI Identifier: oai:expeditiorepositorio.utadeo.edu.co:20.500.12010/14298
• Acceso en línea: https://doi.org/10.1016/j.hemonc.2020.08.002; http://hdl.handle.net/20.500.12010/14298
• Palabra clave: COVID-19; Lenalidomide-based therapy; Myeloma patients; Síndrome respiratorio agudo grave; COVID-19; SARS-CoV-2; Coronavirus
• License: Abierto (Texto Completo)